a cohort study to verify the influences of CYP2C19 phenotype on antiplatelet effectiveness in hemodialysis patients with CAD and/or PAD

a cohort study to verify the influences of CYP2C19 phenotype on antiplatelet effectiveness in hemodialysis patients with CAD and/or PAD - HD-DAPT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014739

Enrollment

300

Registered

2014-08-01

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease Peripheral Artery Disease End-Stage Renal Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients under taking double antiplatelet therapy or planning it

Exclusion criteria

Exclusion criteria: Inappropriate patients for this study judged by the physicians.

Design outcomes

Primary

Measure	Time frame
MACE(cardiovascular death, MI, Stroke, TIA),Major bleeding,Other adverse events	—

Countries

Japan

Contacts

Public ContactTakashi Sakakibara

Nagoya Kyritsu Hospital Department of Cardiology

tsakakibara@kaikou.or.jp052-362-5151

Outcome results